ArticleEndocrine2003
Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure.
Article in Endocrine, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03764020 (A Triple Blinded Randomized Controlled Trial of Oral Melatonin in Elevated Blood Pressure Individual), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Triple Blinded Randomized Controlled Trial of Oral Melatonin in Elevated Blood Pressure Individual (MRCTEBP)
Who cites it
18 citing papers in PubMed, 54 citations in OpenAlex.
- Melatonin supplementation improves N-terminal pro-B-type natriuretic peptide levels and quality of life in patients with heart failure with reduced ejection fraction: Results from MeHR trial, a randomized clinical trial.Clinical cardiology · 2022Trial
- New Perspectives on the Role and Therapeutic Potential of Melatonin in Cardiovascular Diseases.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Review
- Can melatonin reduce the severity of post-COVID-19 syndrome?EXCLI journal · 2023Review
- Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs.BMC veterinary research · 2022Article
- Melatonin: Manager of psychosomatic and metabolic disorders in polymorbid cardiovascular pathology.Frontiers in neuroscience · 2022Article
- Evidence for the Benefits of Melatonin in Cardiovascular Disease.Frontiers in cardiovascular medicine · 2022Review
- Review
- Melatonin to Rescue the Aged Heart: Antiarrhythmic and Antioxidant Benefits.Oxidative medicine and cellular longevity · 2021Review
- Is Melatonin the Cornucopia of the 21st Century?Antioxidants (Basel, Switzerland) · 2020Review
- Aerobic exercise enhanced endothelium-dependent vasorelaxation in mesenteric arteries in spontaneously hypertensive rats: the role of melatonin.Hypertension research : official journal of the Japanese Society of Hypertension · 2018Article
- Melatonin in Heart Failure: A Promising Therapeutic Strategy?Molecules (Basel, Switzerland) · 2018Review
- Cardiovascular Benefits of Dietary Melatonin: A Myth or a Reality?Frontiers in physiology · 2018Review
- Inhibition of VEGF-Induced VEGFR-2 Activation and HUVEC Migration by Melatonin and Other Bioactive Indolic Compounds.Nutrients · 2017Article
- Melatonin suppresses hypoxia-induced migration of HUVECs via inhibition of ERK/Rac1 activation.International journal of molecular sciences · 2014Article
- Measurement of melatonin in body fluids: standards, protocols and procedures.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2011Article
- MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries.The Journal of pharmacology and experimental therapeutics · 2011Article
- Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value.International journal of Alzheimer's disease · 2010Article
- Diabetes and atherothrombosis: The circadian rhythm and role of melatonin in vascular protection.Diabetes & vascular disease researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess urinary 6-sulfatoxymelatonin excretion in patients admitted to the hospital because of congestive heart failure (CHF).
methodsUrinary 6-sulfatoxymelatonin was measured by a specific radioimmunoassay in 33 hospitalized patients with CHF and in 146 healthy ambulatory volunteers. Individuals with hepatic or renal failure were excluded from the sample. Data were analyzed by the Mann-Whitney test and regression analysis.
results6-Sulfatoxymelatonin levels were significantly lower in CHF patients than controls (median 2.6 vs 6.02 microg, p < 0.0001). This decrease was observed regardless of beta-adrenergic blocker or benzodiazepine medication. A significant decrease in 6-sulfatoxymelatonin excretion occurred with age. There were no significant differences in urinary 6-sulfatoxymelatonin levels between chronic and acute CHF patients.
conclusionsThe results suggest that circulating melatonin levels are low in patients with CHF. Such a decrease may precede aggravation of heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.